Skip to main content

‘Activist’ shareholder demands change at Elementis

1st May 2024

Submitted by:

Andrew Warmington

Gatemore Capital Management has published an open letter to John O’Higgins, chairman of the board at UK-based speciality chemicals company Elementis, stating that there is “an urgent need for change”. This echoes a letter from another ‘activist’ shareholder in late 2023.

Elementis mainly supplies the personal care sector, notably cosmetic and antiperspirant actives – it is the world market leader in the latter field. 85% of its products are of natural origin. Coatings and paper are other key markets.

Gatemore, which has a 0.6% stake, said that there is a between the firm’s “fundamental strength” and its “persistently weak share price. Having already engaged to this effect, it said that is going public about how Elementis should act “to rebuild investor confidence and unlock significant value for its shareholders”.

According to Gatemore, Elementis “is an attractive business that has lost its direction” and should be doing better, based on various factors:  the importance of rheology modifiers in product formulation; customer loyalty, especially in coatings; owning a hectorite mine in California, which is a key competitive advantage; expertise in rheology modifiers with market-leading R&D capabilities; and consistently strong historical gross profit margins.

Nonetheless, its performance has been very weak and this, Gatemore said, is largely self-inflicted. This it blamed above all on CEO Paul Waterman. Since he took over in 2016, Elementis has total shareholder returns 86% lower than its peers and 76% lower than the FTSE 250, despite three takeover approaches boosting the share price.

In particular, Gatemore cited: poor capital allocation with a $650 million net spend on M&A, over a half of its current entire market capitalisation, most obviously overspending on Mondo Minerals; repeated operational underperformance; and rejecting three takeover approaches from Minerals Technologies and Innospec in 2020-1.

In addition, Gartmore said, “Elementis’ self-help measures are woefully inadequate”. The $20 million ‘Fit for Future’ cost-saving programme announced at a Capital Markets Day in November 2023 could and should have been implemented earlier, while analysts remain sceptical abut the management’s ability to deliver its EBIT targets. Gatemore concluded by asking the company to:

* Accelerate and confirm the details around the programme

* Replace Waterman and appoint new non-executive director Heejae Chae to lead the search process

* Conduct a strategic review of the portfolio with the aim of refocusing and making it more attractive for a strategic buyer

Gatemore added that it had spoken to other shareholders and believed that most were in agreement. Furthermore, it claimed to have “a strong track record of unlocking value in UK small- and mid-caps for all shareholders”, citing DX Group as an example.

Elementis did not directly respond. Instead, it said: ‘The board continues to believe that shareholder value is best driven by a focus on delivering the substantial actions that are currently being progressed at pace throughout the business and that underpin progress towards the 2026 targets of 19%+ operating margin, over 90% cash conversion and over 20% return on capital, generated by $90 million of above market revenue growth and $30 million cost savings.”

In November 2023, another activist, Franklin Mutual Advisers, had published a similar open letter O’Higgins, calling for Elementis to put itself up for sale. It accused the company of “a shocking amount of shareholder value destruction”, mainly from buying SummitReheis and Mondo Minerals. Elementis declined, saying it did not think this to be in shareholders’ best interests.

Feature article – Saltigo rides out the cycle

Market and sustainability trends are positive drivers for Saltigo, despite the agro downturn. Andrew Warmington met up with the new CEO at Chemspec Europe

Submitted by:

Andrew Warmington

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical active ingredient (AI) manufacturing to its wholly owned subsidiary UPL Spec

Submitted by:

Andrew Warmington

Nippon Shokubai opens Indonesian plant

Japan’s Nippon Shokubai has officially opened a 100,000 tonnes/year acrylic acid (AA) plant that was built at a cost of about $200 million at Cilegon, Banten, Indonesia.

Submitted by:

Andrew Warmington

CABB to invest at Finnish agro site

The CABB Group has said that it will invest over €50 million by 2025 to expand facilities at its agrochemical manufacturing site in Kokkola, Finland.

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operati

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after a week after the latter declined to engage with it.

Submitted by:

Andrew Warmington

adcs

Three invest further into ADCs

Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.

Submitted by:

Andrew Warmington

Cambrex exits drug product

CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed.

Submitted by:

Andrew Warmington

Siegfried breaks ground on R&D centre

Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland.

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants under the trade names AmphiCare and AmphiClean.

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based subsidiary of Seqens.

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in Austria have co-developed a computer-assisted regression model to improve enzyme performance and

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU and the Bio-based Industries Consortium (BIC) that funds projects advancing competitive circular bi

Submitted by:

Andrew Warmington

Investment in Tanasote plant

Octowood, a part of the Sweden’s Rundvirke Industrier Group, has invested in a new treatment plant using Arxada’s wood preservative, Tanasote.

Submitted by:

Andrew Warmington

Rhamnolipid milestone reached

Evonik has manufactured the first product from its industrial-scale biosurfactants facility at Slovenská Lupca in Slovakia.

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach Group in a move that it said would “create a global pigment company, combining SCIL’s ope

Submitted by:

Andrew Warmington

Lanxess to continue pigment production

Lanxess has reversed a decision to sell the chromium oxide pigments business at the Krefeld-Uerdingen site in Germany, preserving 50 jobs there.

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw materials, has announced a strategic collaboration with Japan’s Takasago, a large player in th

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site in Guangzhou. This triples its manufacturing capacity for fragrances and establis

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable fragrance ingredients from renewable carbon, with US-based LanzaTech, which describes i

Submitted by:

Andrew Warmington

Kao boosts jasmine fragrance

Japan's Kao Corporation is to double capacity for the synthetic fragrance methyl dihydrojasmonate (MDJ) at its site in Olesa, Spain, by adding a second production facility.

Submitted by:

Andrew Warmington

Merck KGaA “in a strong strategic position”

At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitio

Submitted by:

Andrew Warmington

Suez joins Global Impact Coalition

Suez, which describes itself as “a global leader in circular solutions for water and waste”, has joined the Global Impact Coalition (GIC).

Submitted by:

Andrew Warmington

Chemours opens battery lab

Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware.

Submitted by:

Andrew Warmington